build_ard()

Runs each analysis in analysis.yaml — built-in or the display's own custom.R — over the prepared datasets and stacks the results into the ARD, one row per statistic, with the population record.

Inputs

analysis.yamlwhat to compute
custom.Rwhere a built-in method does not fit
prepared datasets
the study modelarms in print order

Function

build_ard()pipeline/R/ard.R

Outputs

ARD rowsopencsr/ard/v1, plus the population record

Code: pipeline/R/ard.R

Produced

t-demographics Demographic and Baseline Characteristics · v007
t-disposition Subject Disposition · v003
t-populations Summary of Populations · v003
t-end-of-study Summary of End of Study Data · v003
f-derm-time-to-event Time to Dermatologic Event by Treatment Group · v002
t-cibic-week24 Primary Endpoint Analysis: CIBIC+ — Summary at Week 24 — LOCF · v004
t-cibic-week8 CIBIC+ — Summary at Week 8 — LOCF · v002
t-cibic-week16 CIBIC+ — Summary at Week 16 — LOCF · v002
t-cibic-categorical CIBIC+ — Categorical Analysis — LOCF · v002
t-eff-adas-wk24 Primary Endpoint Analysis: ADAS-Cog (11) - Change from Baseline to Week 24 - LOCF · v002
t-eff-adas-wk8 ADAS-Cog (11) - Change from Baseline to Week 8 - LOCF · v002
t-eff-adas-wk16 ADAS-Cog (11) - Change from Baseline to Week 16 - LOCF · v002
t-eff-adas-wk24-completers ADAS-Cog (11) - Change from Baseline to Week 24 - Completers at Week 24, Observed Cases, Windowed · v002
t-eff-adas-wk24-male ADAS-Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF · v002
t-eff-adas-wk24-female ADAS-Cog (11) - Change from Baseline to Week 24 in Female Subjects - LOCF · v002
t-eff-adas-overtime ADAS-Cog (11) - Mean and Mean Change from Baseline over Time · v002
t-eff-adas-mmrm ADAS-Cog (11) - Repeated Measures Analysis of Change from Baseline to Week 24 · v004
t-eff-npix-mean Mean NPI-X Total Score from Week 4 through Week 24 - Windowed · v003
t-ae-overview Overview of Treatment-Emergent Adverse Events · v003
t-ae-common Treatment-Emergent Adverse Events by System Organ Class and Preferred Term · v004
t-exposure Extent of Exposure to Study Drug · v004
l-ae-serious Listing of Serious Adverse Events · v003
t-conmeds Summary of Concomitant Medications · v003
t-vitals Summary of Vital Signs at Baseline and End of Treatment · v002
t-vitals-change Summary of Vital Signs Change from Baseline at End of Treatment · v002
t-weight Summary of Weight and Weight Change from Baseline at End of Treatment · v004
t-ae-incidence Incidence of Treatment Emergent Adverse Events by Treatment Group · v007
t-sae-incidence Incidence of Treatment Emergent Serious Adverse Events by Treatment Group · v006
t-subjects-by-site Summary of Number of Subjects By Site · v002
f-disposition Subject Disposition · v001